The foregoing release contains certain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
Forward- looking statements include statements regarding Alseres' future
expectations, beliefs, intentions, goals, strategies, plans or prospects
regarding the future, including the development and commercialization of
Altropane and Cethrin, the prospects of the Company's CNS and regenerative
therapeutics programs, the Company's strategies to develop and
commercialize axon regeneration technologies and the breadth of the
Company's technologies and intellectual property portfolio. Forward-looking
statements can be identified by terminology such as "anticipate,"
"believe," "could," "could increase the likelihood," "estimate," "expect,"
"intend," "is planned," "may," "should," "will," "will enable," "would be
expected," "look forward," "may provide," "would" or similar terms,
variations of such terms or the negative of those terms. Such
forward-looking statements involve known and unknown risks, uncertainties
and other factors including those risks, uncertainties and factors referred
to in the Company's Annual Report on Form 10-K for the year ended December
31, 2007 filed with the Securities and Exchange Commission under the
section "Risk Factors," as well as other documents that may be filed by
Alseres from time to time with the Securities and Exchange Commission. As a
result of such risks, uncertainties and factors, the Company's actual
results may differ materially from any fut
|SOURCE Alseres Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved